FDA Nod for Quidel's hMPV Test - Analyst Blog

By
A A A

Leading diagnostic test solutions provider Quidel Corporation ( QDEL">QDEL ) has won the approval of the U.S. Food and Drug Administration ("FDA") for its new virus test dubbed the"Quidel MolecularhMPV Assay". The test is designed for the detection of humanmetapneumovirus (hMPV ) infection.

TheQuidel MolecularhMPV is among the several promising upcoming assays from the California-based company's expanding molecular diagnostics programs.Quidel received European CE Mark for the test in September 2011. The FDA approval enables the company to market theQuidel MolecularhMPV assay in the U.S. ahead the forthcoming respiratory disease season.  

Identified in 2001 by investigators from the Netherlands,hMPV is the second most common cause (after respiratorysyncytial virus/RSV) of upper and lower respiratory infection in young children. Studies have shown that most children are exposed tohMPV infection by the age of five. The condition which manifests itself through symptoms such as cough, runny nose, nasal congestion and fever, affects roughly 7% of children who are hospitalized with respiratory infection.

Quidel noted that theQuidel MolecularhMPV assay is its first molecular diagnostic test to be cleared for marketing in the U.S. The company's rapidly expanding range of molecular diagnostics tests is expected to offer a number of important benefits to the end-users including increased ease of use and lower processing time.

Quidel develops and markets diagnostic solutions aimed at improving patient outcomes and offering economic benefits to the healthcare system. The company's products are designed to detect and diagnose a host of critical diseases such as influenza, RSV, herpes and thyroid disease.Quidel competes with Alere Inc ( ALR">ALR ), among others.

Quidel's sales in third-quarter fiscal 2011 soared 17% year over year led by its tests for infectious diseases. The company registered healthy growth across its Strep A (up 10% year over year) and RSV (more than doubled year over year) product lines in the quarter.


 
ALERE INC ( ALR ): Free Stock Analysis Report
 
QUIDEL CORP ( QDEL ): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ALR , QDEL

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Budgeting for Baby
Budgeting for Baby                  
A Home to Retire In
A Home to Retire In                 

Stocks

Referenced

50%
100%

Most Active by Volume

86,692,048
  • $16.82 ▼ 1.35%
66,073,054
  • $13.30 ▼ 6.27%
54,801,491
  • $14.59 ▼ 1.35%
54,305,010
  • $76.55 ▼ 3.15%
53,982,567
  • $3.42 ▼ 2.01%
53,146,472
  • $97.21 ▼ 1.60%
50,334,521
  • $99.18 ▼ 1.56%
44,049,276
  • $25.03 ▼ 0.56%
As of 10/1/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com